The paradigms of clinical trial execution are evolving rapidly as pharma companies embrace the ideas of decentralized, remote and virtual clinical trials. These concepts are explored in Part 1 of this series and play an increasingly important role in the current paradigm of trial execution – and will continue to do so in the future. In Part 2 of this series, we explore the concept of real-world data in clinical trials. As noted by Mark Lambrecht, PhD, Director of the EMEA and APAC Health and Life Sciences Practice at SAS, “This next wave of clinical trial design will combine the best of both worlds: the gold standard randomized controlled trials (RCTs) and the ability to adapt the design based on real-world data.